OncoMatch/Clinical Trials/NCT06539338
A Study to Investigate Safety of INT2104 Infusions in Participants Aged 18 Years of Age and Older Who Have B-cell Cancers That Came Back After Previous Treatment
Is NCT06539338 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies non-drug interventions for lymphomas non-hodgkin's b-cell.
The purpose of this first-in-human study is to evaluate the safety and tolerability of INT2104 when administered to humans in a broad population of participants with refractory/relapsing B-cell malignancies. Preliminary efficacy information may also be obtained. INT2104 is a gene therapy delivering a transgene for a chimeric antigen receptor (CAR) specific for CD20 (CAR20). The lentiviral vector is designed to generate CAR T and CAR Natural Killer (NK) cells inside the body following intravenous (IV) administration. Study details include the following: * The study duration will be 5 years * The treatment duration will be a one-time intravenous (IV) infusion of INT2104
Check if I qualifyExtracted eligibility criteria
Cancer type
Acute Lymphoblastic Leukemia
Non-Hodgkin Lymphoma
Biomarker criteria
Required: MS4A1 antigen positive
B-NHL must have CD20 antigen positive tumour confirmed from a tumour biopsy taken at screening
Required: MS4A1 antigen positive
B-ALL participants must have CD20 antigen positive leukaemia
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: systemic therapy
Progression after at least 2 lines of systemic therapy
Cannot have received: CAR-T cell therapy or other genetically modified T-cell therapy
Exception: no more than one prior marketed CAR-T cell therapy (including tandem or bispecific CAR-T)
Has not received more than one prior marketed CAR-T cell therapy (including tandem or bispecific CAR-T) or other genetically modified T-cell therapy.
Cannot have received: donor lymphocyte infusion
Exception: within 6 weeks prior to INT2104 infusion
Participant has received donor lymphocyte infusion within 6 weeks prior to INT2104 infusion
Lab requirements
Blood counts
absolute lymphocyte count (alc) ≥300/µl; platelet count ≥50,000/ml; absolute neutrophil count (anc) ≥500/µl
Kidney function
adequate renal function
Liver function
adequate hepatic function
Cardiac function
adequate cardiac function
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify